Limitations of current Parkinson's disease therapy
Identifieur interne : 001074 ( Istex/Corpus ); précédent : 001073; suivant : 001075Limitations of current Parkinson's disease therapy
Auteurs : Olivier Rascol ; Pierre Payoux ; Fabienne Ory ; Joaquim J. Ferreira ; Christine Brefel-Courbon ; Jean-Louis MontastrucSource :
- Annals of Neurology [ 0364-5134 ] ; 2003.
Abstract
Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15
Url:
DOI: 10.1002/ana.10513
Links to Exploration step
ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Limitations of current Parkinson's disease therapy</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM U455, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><affiliation><mods:affiliation>INSERM U455, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Nuclear Medicine, Toulouse, University Hospital France</mods:affiliation></affiliation></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM U455, Toulouse, University Hospital France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/ana.10513</idno><idno type="url">https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001074</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001074</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Limitations of current Parkinson's disease therapy</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM U455, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><affiliation><mods:affiliation>INSERM U455, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Nuclear Medicine, Toulouse, University Hospital France</mods:affiliation></affiliation></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM U455, Toulouse, University Hospital France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation><mods:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003">2003</date><biblScope unit="volume">53</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">3</biblScope><biblScope unit="page" from="S3">S3</biblScope><biblScope unit="page" to="S15">S15</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno><idno type="DOI">10.1002/ana.10513</idno><idno type="ArticleID">ANA10513</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</json:string><json:string>INSERM U455, Toulouse, University Hospital France</json:string><json:string>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</json:string></affiliations></json:item><json:item><name>Pierre Payoux MD</name><affiliations><json:string>INSERM U455, Toulouse, University Hospital France</json:string><json:string>Department of Nuclear Medicine, Toulouse, University Hospital France</json:string></affiliations></json:item><json:item><name>Fabienne Ory MD</name><affiliations><json:string>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</json:string></affiliations></json:item><json:item><name>Joaquim J. Ferreira MD</name><affiliations><json:string>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</json:string><json:string>Department of Neurology, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Christine Brefel‐Courbon MD</name><affiliations><json:string>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</json:string><json:string>INSERM U455, Toulouse, University Hospital France</json:string></affiliations></json:item><json:item><name>Jean‐Louis Montastruc MD, PhD</name><affiliations><json:string>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</json:string></affiliations></json:item></author><articleId><json:string>ANA10513</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</abstract><qualityIndicators><score>6.404</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 801 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>891</abstractCharCount><pdfWordCount>9391</pdfWordCount><pdfCharCount>61259</pdfCharCount><pdfPageCount>13</pdfPageCount><abstractWordCount>117</abstractWordCount></qualityIndicators><title>Limitations of current Parkinson's disease therapy</title><refBibs><json:item><author><json:item><name>GC Cotzias</name></json:item><json:item><name>MH Van Woert</name></json:item><json:item><name>LM Schiffer</name></json:item></author><host><volume>276</volume><pages><last>379</last><first>374</first></pages><author></author><title>N Engl J Med</title></host><title>Aromatic amino acids and modification of parkinsonism</title></json:item><json:item><author><json:item><name>C Goetz</name></json:item><json:item><name>W Koller</name></json:item><json:item><name>W Poewe</name></json:item></author><host><volume>17</volume><pages><last>166</last><first>1</first></pages><issue>suppl 4</issue><author></author><title>Mov Disord</title></host><title>Management of Parkinson's disease: an evidence‐based review</title></json:item><json:item><author><json:item><name>AJ Hughes</name></json:item><json:item><name>SE Daniel</name></json:item><json:item><name>AJ Lees</name></json:item></author><host><volume>57</volume><pages><last>1499</last><first>1497</first></pages><author></author><title>Neurology</title></host><title>Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease</title></json:item><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>P Cervera</name></json:item><json:item><name>E Hirsch</name></json:item></author><host><volume>4</volume><pages><last>144</last><first>126</first></pages><author></author><title>Mov Disord</title></host><title>Biochemistry of Parkinson's disease 28 years later: a critical review</title></json:item><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>H Taquet</name></json:item><json:item><name>F Cesselin</name></json:item></author><host><volume>66</volume><pages><last>116</last><first>107</first></pages><author></author><title>Prog Brain Res</title></host><title>Neuropeptides and Parkinson's disease</title></json:item><json:item><author><json:item><name>B Dubois</name></json:item><json:item><name>JJ Hauw</name></json:item><json:item><name>M Ruberg</name></json:item></author><host><volume>141</volume><pages><last>193</last><first>184</first></pages><author></author><title>Rev Neurol</title></host><title>Dementia and Parkinson's disease: biochemical and anatomo‐clinical correlation</title></json:item><json:item><author><json:item><name>B Pillon</name></json:item><json:item><name>B Dubois</name></json:item><json:item><name>G Cusimano</name></json:item></author><host><volume>52</volume><pages><last>206</last><first>201</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Does cognitive impairment in Parkinson's disease result from non‐dopaminergic lesions?</title></json:item><json:item><author><json:item><name>K Wakabayashi</name></json:item><json:item><name>H Takahashi</name></json:item></author><host><volume>38</volume><pages><last>7</last><first>2</first></pages><author></author><title>Eur Neurol</title></host><title>Neuropathology of autonomic nervous system in Parkinson's disease</title></json:item><json:item><author><json:item><name>J Jankovic</name></json:item><json:item><name>AS Kapadia</name></json:item></author><host><volume>58</volume><pages><last>1615</last><first>1611</first></pages><author></author><title>Arch Neurol</title></host><title>Functional decline in Parkinson disease</title></json:item><json:item><author><json:item><name>M Gentil</name></json:item><json:item><name>P Pollak</name></json:item><json:item><name>J Perret</name></json:item></author><host><volume>151</volume><pages><last>112</last><first>105</first></pages><author></author><title>Rev Neurol (Paris)</title></host><title>Parkinsonian dysarthria</title></json:item><json:item><author><json:item><name>BR Bloem</name></json:item><json:item><name>JP van Vugt</name></json:item><json:item><name>DJ Beckley</name></json:item></author><host><volume>87</volume><pages><last>223</last><first>209</first></pages><author></author><title>Adv Neurol</title></host><title>Postural instability and falls in Parkinson's disease</title></json:item><json:item><author><json:item><name>N Giladi</name></json:item><json:item><name>R Kao</name></json:item><json:item><name>S Fahn</name></json:item></author><host><volume>12</volume><pages><last>305</last><first>302</first></pages><author></author><title>Mov Disord</title></host><title>Freezing phenomenon in patients with parkinsonian syndromes</title></json:item><json:item><author><json:item><name>N Giladi</name></json:item></author><host><volume>86</volume><pages><last>278</last><first>273</first></pages><author></author><title>Adv Neurol</title></host><title>Gait disturbances in advanced stages of Parkinson's disease</title></json:item><json:item><author><json:item><name>AM Bonnet</name></json:item><json:item><name>Y Loria</name></json:item><json:item><name>MH Saint‐Hilaire</name></json:item></author><host><volume>37</volume><pages><last>1542</last><first>1539</first></pages><author></author><title>Neurology</title></host><title>Does long‐term aggravation of Parkinson's disease result from non dopaminergic lesions?</title></json:item><json:item><author><json:item><name>A Ashburn</name></json:item><json:item><name>E Stack</name></json:item><json:item><name>RM Pickering</name></json:item><json:item><name>CD Ward</name></json:item></author><host><volume>30</volume><pages><last>52</last><first>47</first></pages><author></author><title>Age Ageing</title></host><title>A community‐dwelling sample of people with Parkinson's disease: characteristics of fallers and non‐fallers</title></json:item><json:item><author><json:item><name>JM Senard</name></json:item><json:item><name>S Rai</name></json:item><json:item><name>M Lapeyre‐Mestre</name></json:item></author><host><volume>63</volume><pages><last>589</last><first>584</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Prevalence of orthostatic hypotension in Parkinson's disease</title></json:item><json:item><author><json:item><name>JM Senard</name></json:item><json:item><name>C Brefel‐Courbon</name></json:item><json:item><name>O Rascol</name></json:item><json:item><name>JL Montastruc</name></json:item></author><host><volume>18</volume><pages><last>505</last><first>495</first></pages><author></author><title>Drugs Aging</title></host><title>Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management</title></json:item><json:item><author><json:item><name>E Martignoni</name></json:item><json:item><name>C Pacchetti</name></json:item><json:item><name>L Godi</name></json:item></author><host><volume>45</volume><pages><last>19</last><first>11</first></pages><issue>Suppl</issue><author></author><title>J Neural Transm</title></host><title>Autonomic disorders in Parkinson's disease</title></json:item><json:item><author><json:item><name>CJ Mathias</name></json:item></author><host><volume>69</volume><pages><last>391</last><first>383</first></pages><author></author><title>Adv Neurol</title></host><title>Disorders affecting autonomic function in parkinsonian patients</title></json:item><json:item><author><json:item><name>KR Chaudhuri</name></json:item></author><host><volume>14</volume><pages><last>511</last><first>505</first></pages><author></author><title>Curr Opin Neurol</title></host><title>Autonomic dysfunction in movement disorders</title></json:item><json:item><author><json:item><name>JL Cummings</name></json:item><json:item><name>DL Masterman</name></json:item></author><host><volume>14</volume><pages><last>718</last><first>711</first></pages><author></author><title>Int J Geriatr Psychiatry</title></host><title>Depression in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>R Mayeux</name></json:item><json:item><name>J Denaro</name></json:item><json:item><name>N Hemenegildo</name></json:item></author><host><volume>49</volume><pages><last>497</last><first>492</first></pages><author></author><title>Arch Neurol</title></host><title>A population‐based investigation of Parkinson's disease with and without dementia. Relationship to age and gender</title></json:item><json:item><author><json:item><name>IG McKeith</name></json:item></author><host><volume>180</volume><pages><last>147</last><first>144</first></pages><author></author><title>Br J Psychiatry</title></host><title>Dementia with Lewy bodies</title></json:item><json:item><author><json:item><name>AJ Lees</name></json:item><json:item><name>NA Blackburn</name></json:item><json:item><name>VL Campbell</name></json:item></author><host><volume>11</volume><pages><last>519</last><first>512</first></pages><author></author><title>Clin Neuropharmacol</title></host><title>The nighttime problems of Parkinson's disease</title></json:item><json:item><author><json:item><name>JP Larsen</name></json:item><json:item><name>E Tandberg</name></json:item></author><host><volume>15</volume><pages><last>275</last><first>267</first></pages><author></author><title>CNS Drugs</title></host><title>Sleep disorders in patients with Parkinson's disease: epidemiology and management</title></json:item><json:item><author><json:item><name>EK Tan</name></json:item><json:item><name>SY Lum</name></json:item><json:item><name>SM Fook‐Chong</name></json:item></author><host><volume>58</volume><pages><last>468</last><first>465</first></pages><author></author><title>Neurology</title></host><title>Evaluation of somnolence in Parkinson's disease: comparison with age‐ and sex‐matched controls</title></json:item><json:item><author><json:item><name>S Waseem</name></json:item><json:item><name>K Gwinn‐Hardy</name></json:item></author><host><volume>110</volume><pages><last>34</last><first>33</first></pages><author></author><title>Postgrad Med</title></host><title>Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable</title></json:item><json:item><author><json:item><name>PK Morrish</name></json:item><json:item><name>JS Rakshi</name></json:item><json:item><name>DL Bailey</name></json:item></author><host><volume>64</volume><pages><last>319</last><first>314</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item></author><host><volume>49</volume><pages><last>33</last><first>26</first></pages><author></author><title>Neurology</title></host><title>Attempts to obtain neuroprotection in Parkinson's disease</title></json:item><json:item><author><json:item><name>B Drukarch</name></json:item><json:item><name>FL van Muiswinkel</name></json:item></author><host><volume>10</volume><pages><last>1868</last><first>1855</first></pages><author></author><title>Expert Opin Invest Drugs</title></host><title>Neuroprotection for Parkinson's disease: a new approach for a new millennium</title></json:item><json:item><author><json:item><name>GC Palmer</name></json:item></author><host><volume>2</volume><pages><last>271</last><first>241</first></pages><author></author><title>Curr Drug Targets</title></host><title>Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>328</volume><pages><last>183</last><first>176</first></pages><author></author><title>N Engl J Med</title></host><title>Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>RA Hauser</name></json:item><json:item><name>L Gauger</name></json:item></author><host><volume>38</volume><pages><last>777</last><first>771</first></pages><author></author><title>Ann Neurol</title></host><title>The effect of deprenyl and levodopa on the progression of Parkinson's disease</title></json:item><json:item><author><json:item><name>MM Hoehn</name></json:item><json:item><name>MD Yahr</name></json:item></author><host><volume>17</volume><pages><last>442</last><first>427</first></pages><author></author><title>Neurology</title></host><title>Parkinsonism: onset, progression and mortality</title></json:item><json:item><author><json:item><name> </name></json:item><json:item><name> </name></json:item></author><host><volume>43</volume><pages><last>325</last><first>318</first></pages><author></author><title>Ann Neurol</title></host><title>Mortality in DATATOP: a multicenter trial in early Parkinson's disease</title></json:item><json:item><author><json:item><name>M Guttman</name></json:item><json:item><name>D Stewart</name></json:item><json:item><name>D Hussey</name></json:item></author><host><volume>56</volume><pages><last>1564</last><first>1559</first></pages><author></author><title>Neurology</title></host><title>Influence of L‐dopa and pramipexole on striatal dopamine transporter in early PD</title></json:item><json:item><author><json:item><name>AJ Lees</name></json:item><json:item><name>R Katzenschlager</name></json:item><json:item><name>J Head</name></json:item><json:item><name>Y Ben‐Shlomo</name></json:item></author><host><volume>57</volume><pages><last>1694</last><first>1687</first></pages><author></author><title>Neurology</title></host><title>Ten‐year follow‐up of three different initial treatments in de‐novo PD: a randomized trial</title></json:item><json:item><author><json:item><name>IY Bodagh</name></json:item><json:item><name>DR Robertson</name></json:item></author><host><volume>11</volume><pages><last>103</last><first>94</first></pages><author></author><title>Drug Saf</title></host><title>A risk‐benefit assessment of drugs used in the management of Parkinson's disease</title></json:item><json:item><author><json:item><name>H Shill</name></json:item><json:item><name>M Stacy</name></json:item></author><host><volume>5</volume><pages><last>135</last><first>131</first></pages><author></author><title>Clin Neurosci</title></host><title>Respiratory function in Parkinson's disease</title></json:item><json:item><author><json:item><name>S Kaakkola</name></json:item></author><host><volume>59</volume><pages><last>1250</last><first>1233</first></pages><author></author><title>Drugs</title></host><title>Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease</title></json:item><json:item><author><json:item><name>EK Tan</name></json:item><json:item><name>W Ondo</name></json:item></author><host><volume>57</volume><pages><last>732</last><first>729</first></pages><author></author><title>Arch Neurol</title></host><title>Clinical characteristics of pramipexole‐induced peripheral edema</title></json:item><json:item><author><json:item><name>A Alkhani</name></json:item><json:item><name>AM Lozano</name></json:item></author><host><volume>94</volume><pages><last>49</last><first>43</first></pages><author></author><title>J Neurosurg</title></host><title>Pallidotomy for Parkinson disease: a review of contemporary literature</title></json:item><json:item><author><json:item><name>SA Factor</name></json:item><json:item><name>ES Molho</name></json:item><json:item><name>GD Podskalny</name></json:item><json:item><name>D Brown</name></json:item></author><host><volume>65</volume><pages><last>138</last><first>115</first></pages><author></author><title>Adv Neurol</title></host><title>Parkinson's disease: drug‐induced psychiatric states</title></json:item><json:item><author><json:item><name>JA Obeso</name></json:item><json:item><name>CW Olanow</name></json:item><json:item><name>JG Nutt</name></json:item></author><host><volume>23</volume><pages><last>7</last><first>2</first></pages><author></author><title>Trends Neurosci</title></host><title>Levodopa motor complications in Parkinson's disease</title></json:item><json:item><author><json:item><name>JA Obeso</name></json:item><json:item><name>MC Rodriguez‐Oroz</name></json:item><json:item><name>P Chana</name></json:item></author><host><volume>55</volume><pages><last>20</last><first>13</first></pages><author></author><title>Neurology</title></host><title>The evolution and origin of motor complications in Parkinson's disease</title></json:item><json:item><author><json:item><name>JE Ahlskog</name></json:item><json:item><name>MD Muenter</name></json:item></author><host><volume>16</volume><pages><last>458</last><first>448</first></pages><author></author><title>Mov Disord</title></host><title>Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature</title></json:item><json:item><author><json:item><name>G Fabbrini</name></json:item><json:item><name>MM Mouradian</name></json:item><json:item><name>JL Juncos</name></json:item></author><host><volume>24</volume><pages><last>371</last><first>366</first></pages><author></author><title>Ann Neurol</title></host><title>Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I</title></json:item><json:item><author><json:item><name>MM Mouradian</name></json:item><json:item><name>JL Juncos</name></json:item><json:item><name>G Fabbrini</name></json:item></author><host><volume>24</volume><pages><last>378</last><first>372</first></pages><author></author><title>Ann Neurol</title></host><title>Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II</title></json:item><json:item><author><json:item><name>D Bravi</name></json:item><json:item><name>MM Mouradian</name></json:item><json:item><name>JW Roberts</name></json:item></author><host><volume>36</volume><pages><last>31</last><first>27</first></pages><author></author><title>Ann Neurol</title></host><title>Wearing‐off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms</title></json:item><json:item><author><json:item><name>L Verhagen Metman</name></json:item><json:item><name>ER Locatelli</name></json:item><json:item><name>D Bravi</name></json:item></author><host><volume>48</volume><pages><last>372</last><first>369</first></pages><author></author><title>Neurology</title></host><title>Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications</title></json:item><json:item><author><json:item><name>W Olanow</name></json:item><json:item><name>AH Schapira</name></json:item><json:item><name>O Rascol</name></json:item></author><host><volume>23</volume><pages><last>126</last><first>117</first></pages><author></author><title>Trends Neurosci</title></host><title>Continuous dopamine‐receptor stimulation in early Parkinson's disease</title></json:item><json:item><author><json:item><name>O Rascol</name></json:item></author><host><volume>14</volume><pages><last>32</last><first>19</first></pages><author></author><title>Mov Disord</title></host><title>L‐dopa‐induced peak‐dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach</title></json:item><json:item><author><json:item><name>E Bezard</name></json:item><json:item><name>JM Brotchie</name></json:item><json:item><name>CE Gross</name></json:item></author><host><volume>2</volume><pages><last>588</last><first>577</first></pages><author></author><title>Nat Rev Neurosci</title></host><title>Pathophysiology of levodopa‐induced dyskinesia: potential for new therapies</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>RL Watts</name></json:item><json:item><name>WC Koller</name></json:item></author><host><volume>56</volume><pages><last>88</last><first>1</first></pages><issue>suppl 5</issue><author></author><title>Neurology</title></host><title>An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines</title></json:item><json:item><author><json:item><name>AE Lang</name></json:item><json:item><name>AM Lozano</name></json:item></author><host><volume>339</volume><pages><last>1143</last><first>1130</first></pages><author></author><title>N Engl J Med</title></host><title>Parkinson's disease. Second of two parts</title></json:item><json:item><author><json:item><name>SM Papa</name></json:item><json:item><name>TN Chase</name></json:item></author><host><volume>39</volume><pages><last>578</last><first>574</first></pages><author></author><title>Ann Neurol</title></host><title>Levodopa‐induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys</title></json:item><json:item><author><json:item><name>AE Lang</name></json:item></author><host><volume>57</volume><pages><last>1125</last><first>1118</first></pages><author></author><title>Arch Neurol</title></host><title>Surgery for Parkinson disease: a critical evaluation of the state of the art</title></json:item><json:item><author><json:item><name>O Rascol</name></json:item><json:item><name>C Goetz</name></json:item><json:item><name>W Koller</name></json:item></author><host><volume>359</volume><pages><last>1598</last><first>1589</first></pages><author></author><title>Lancet</title></host><title>Treatment interventions for Parkinson's disease: an evidence based assessment</title></json:item><json:item><author><json:item><name>O Rascol</name></json:item><json:item><name>DJ Brooks</name></json:item><json:item><name>ER Brunt</name></json:item><json:item><name> </name></json:item></author><host><volume>13</volume><pages><last>45</last><first>39</first></pages><author></author><title>Mov Disord</title></host><title>Ropinirole in the treatment of early Parkinson's disease: a 6‐month interim report of a 5‐year levodopa‐controlled study</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>284</volume><pages><last>1973</last><first>1971</first></pages><author></author><title>JAMA</title></host><title>Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial</title></json:item><json:item><author><json:item><name>E Melamed</name></json:item><json:item><name>D Offen</name></json:item><json:item><name>A Shirvan</name></json:item></author><host><volume>44</volume><pages><last>154</last><first>149</first></pages><author></author><title>Ann Neurol</title></host><title>Levodopa toxicity and apoptosis</title></json:item><json:item><author><json:item><name>MG Murer</name></json:item><json:item><name>G Dziewczapolski</name></json:item><json:item><name>LB Menalled</name></json:item></author><host><volume>43</volume><pages><last>575</last><first>561</first></pages><author></author><title>Ann Neurol</title></host><title>Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions</title></json:item><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>CW Olanow</name></json:item><json:item><name>Y Mizuno</name></json:item></author><host><volume>360</volume><pages><first>575</first></pages><author></author><title>Lancet</title></host><title>Levodopa—why the controversy?</title></json:item><json:item><author><json:item><name>P Barone</name></json:item><json:item><name>D Bravi</name></json:item><json:item><name>F Bermejo‐Pareja</name></json:item><json:item><name> </name></json:item></author><host><volume>53</volume><pages><last>579</last><first>573</first></pages><author></author><title>Neurology</title></host><title>Pergolide monotherapy in the treatment of early PD: a randomized, controlled study</title></json:item><json:item><author><json:item><name>CH Adler</name></json:item><json:item><name>KD Sethi</name></json:item><json:item><name>RA Hauser</name></json:item><json:item><name> </name></json:item></author><host><volume>49</volume><pages><last>399</last><first>393</first></pages><author></author><title>Neurology</title></host><title>Ropinirole for the treatment of early Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item><json:item><name> </name></json:item></author><host><volume>278</volume><pages><last>130</last><first>125</first></pages><author></author><title>JAMA</title></host><title>Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose‐ranging study</title></json:item><json:item><author><json:item><name>MH Corrigan</name></json:item><json:item><name>AQ Denahan</name></json:item><json:item><name>CE Wright</name></json:item></author><host><volume>11</volume><pages><last>65</last><first>58</first></pages><author></author><title>Depress Anxiety</title></host><title>Comparison of pramipexole, fluoxetine, and placebo in patients with major depression</title></json:item><json:item><author><json:item><name>M Guttman</name></json:item><json:item><name> </name></json:item></author><host><volume>49</volume><pages><last>1065</last><first>1060</first></pages><author></author><title>Neurology</title></host><title>Double‐blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease</title></json:item><json:item><author><json:item><name>A Lieberman</name></json:item><json:item><name>CW Olanow</name></json:item><json:item><name>K Sethi</name></json:item><json:item><name> </name></json:item></author><host><volume>51</volume><pages><last>1062</last><first>1057</first></pages><author></author><title>Neurology</title></host><title>A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease</title></json:item><json:item><author><json:item><name>A Colzi</name></json:item><json:item><name>K Turner</name></json:item><json:item><name>AJ Lees</name></json:item></author><host><volume>64</volume><pages><last>576</last><first>573</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease</title></json:item><json:item><author><json:item><name>F Stocchi</name></json:item><json:item><name>S Ruggieri</name></json:item><json:item><name>L Vacca</name></json:item><json:item><name>CW Olanow</name></json:item></author><host><volume>125</volume><pages><last>2066</last><first>2058</first></pages><author></author><title>Brain</title></host><title>Prospective randomized trial of lisuride infusion versus oral levodopa in PD patients</title></json:item><json:item><author><json:item><name>O Rascol</name></json:item><json:item><name>DJ Brooks</name></json:item><json:item><name>AD Korczyn</name></json:item><json:item><name> </name></json:item></author><host><volume>342</volume><pages><last>1491</last><first>1484</first></pages><author></author><title>N Engl J Med</title></host><title>A five‐year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa</title></json:item><json:item><author><json:item><name>UK Rinne</name></json:item><json:item><name>F Bracco</name></json:item><json:item><name>C Chouza</name></json:item><json:item><name> </name></json:item></author><host><volume>55</volume><pages><last>30</last><first>23</first></pages><author></author><title>Drugs</title></host><title>Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double‐blind levodopa controlled trial</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>P Jenner</name></json:item><json:item><name>D Brooks</name></json:item></author><host><volume>44</volume><pages><last>174</last><first>167</first></pages><author></author><title>Ann Neurol</title></host><title>Dopamine agonists and neuroprotection in Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>287</volume><pages><last>1661</last><first>1653</first></pages><author></author><title>JAMA</title></host><title>Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression</title></json:item><json:item><author><json:item><name>AL Whone</name></json:item><json:item><name>P Remy</name></json:item><json:item><name>MR Davis</name></json:item></author><host><volume>58</volume><pages><last>83</last><first>82</first></pages><author></author><title>Neurology</title></host><title>The REAL‐PET Study: slower progression in early Parkinson's disease treated with ropinirole compared with L‐dopa</title></json:item><json:item><author><json:item><name>JL Montastruc</name></json:item><json:item><name>K Desboeuf</name></json:item><json:item><name>M Lapeyre‐Mestre</name></json:item></author><host><volume>16</volume><pages><last>514</last><first>511</first></pages><author></author><title>Mov Disord</title></host><title>Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>40</volume><pages><last>948</last><first>946</first></pages><author></author><title>Ann Neurol</title></host><title>Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item></author><host><volume>47</volume><pages><last>216</last><first>210</first></pages><author></author><title>Neurology</title></host><title>Selegiline: current perspectives on neuroprotection and mortality</title></json:item><json:item><author><json:item><name>W Maruyama</name></json:item><json:item><name>M Naoi</name></json:item></author><host><volume>111</volume><pages><last>200</last><first>189</first></pages><author></author><title>Mech Ageing Dev</title></host><title>Neuroprotection by (‐)‐deprenyl and related compounds</title></json:item><json:item><author><json:item><name>AJ Lees</name></json:item><json:item><name> </name></json:item></author><host><volume>311</volume><pages><last>1607</last><first>1602</first></pages><author></author><title>Br Med J</title></host><title>Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease</title></json:item><json:item><author><json:item><name>Y Ben‐Shlomo</name></json:item><json:item><name>A Churchyard</name></json:item><json:item><name>J Head</name></json:item></author><host><volume>316</volume><pages><last>1196</last><first>1191</first></pages><author></author><title>Br Med J</title></host><title>Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>VV Myllyla</name></json:item><json:item><name>KA Sotaniemi</name></json:item></author><host><volume>51</volume><pages><last>830</last><first>825</first></pages><author></author><title>Neurology</title></host><title>Effect of selegiline on mortality in patients with Parkinson's disease: a meta‐analysis</title></json:item><json:item><author><json:item><name>PT Donnan</name></json:item><json:item><name>DT Steinke</name></json:item><json:item><name>C Stubbings</name></json:item></author><host><volume>55</volume><pages><last>1789</last><first>1785</first></pages><author></author><title>Neurology</title></host><title>Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study</title></json:item><json:item><author><json:item><name>F Assal</name></json:item><json:item><name>L Spahr</name></json:item><json:item><name>A Hadengue</name></json:item></author><host><volume>352</volume><pages><first>958</first></pages><author></author><title>Lancet</title></host><title>Tolcapone and fulminant hepatitis</title></json:item><json:item><author><json:item><name>UK Rinne</name></json:item><json:item><name>JP Larsen</name></json:item><json:item><name>A Siden</name></json:item><json:item><name>J Worm‐Petersen</name></json:item><json:item><name> </name></json:item></author><host><volume>51</volume><pages><last>1314</last><first>1309</first></pages><author></author><title>Neurology</title></host><title>Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>42</volume><pages><last>755</last><first>747</first></pages><author></author><title>Ann Neurol</title></host><title>Entacapone improves motor fluctuations in levodopa‐treated Parkinson's disease patients</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>JA Obeso</name></json:item></author><host><volume>55</volume><pages><last>81</last><first>72</first></pages><author></author><title>Neurology</title></host><title>Pulsatile Stimulation of dopamine receptors and levodopa‐induced motor complications in Parkinson's disease: implications for the early use of COMT Inhibitors</title></json:item><json:item><author><json:item><name>WE Martin</name></json:item><json:item><name>RB Loewenson</name></json:item><json:item><name>JA Resch</name></json:item><json:item><name>AB Baker</name></json:item></author><host><volume>24</volume><pages><last>919</last><first>912</first></pages><author></author><title>Neurology</title></host><title>A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>L Verhagen Metman</name></json:item><json:item><name>P Del Dotto</name></json:item><json:item><name>P van den Munckhof</name></json:item></author><host><volume>50</volume><pages><last>1326</last><first>1323</first></pages><author></author><title>Neurology</title></host><title>Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease</title></json:item><json:item><author><json:item><name>LV Metman</name></json:item><json:item><name>P Del Dotto</name></json:item><json:item><name>K LePoole</name></json:item></author><host><volume>56</volume><pages><last>1386</last><first>1383</first></pages><author></author><title>Arch Neurol</title></host><title>Amantadine for levodopa‐induced dyskinesias: a 1‐year follow‐up study</title></json:item><json:item><author><json:item><name>P Del Dotto</name></json:item><json:item><name>N Pavese</name></json:item><json:item><name>G Gambaccini</name></json:item></author><host><volume>16</volume><pages><last>520</last><first>515</first></pages><author></author><title>Mov Disord</title></host><title>Intravenous amantadine improves levodopa‐induced dyskinesias: an acute double‐blind placebo‐controlled study</title></json:item><json:item><author><json:item><name>RJ Uitti</name></json:item><json:item><name>AH Rajput</name></json:item><json:item><name>JE Ahlskog</name></json:item></author><host><volume>46</volume><pages><last>1556</last><first>1551</first></pages><author></author><title>Neurology</title></host><title>Amantadine treatment is an independent predictor of improved survival in Parkinson's disease</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>MF Brin</name></json:item></author><host><volume>86</volume><pages><last>433</last><first>421</first></pages><author></author><title>Adv Neurol</title></host><title>Surgery for Parkinson's disease: a physician's perspective</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>345</volume><pages><last>963</last><first>956</first></pages><author></author><title>N Engl J Med</title></host><title>Deep‐brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease</title></json:item><json:item><author><json:item><name>CR Freed</name></json:item><json:item><name>PE Greene</name></json:item><json:item><name>RE Breeze</name></json:item></author><host><volume>344</volume><pages><last>719</last><first>710</first></pages><author></author><title>N Engl J Med</title></host><title>Transplantation of embryonic dopamine neurons for severe Parkinson's disease</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item></author><host><volume>17</volume><pages><first>15</first></pages><issue>suppl 5</issue><author></author><title>Mov Disord</title></host><title>Transplantation for Parkinson's disease: pros, cons, and where do we go from here?</title></json:item><json:item><author><json:item><name>I McKeith</name></json:item><json:item><name>T Del Ser</name></json:item><json:item><name>P Spano</name></json:item></author><host><volume>356</volume><pages><last>2036</last><first>2031</first></pages><author></author><title>Lancet</title></host><title>Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled international study</title></json:item><json:item><author><json:item><name> </name></json:item><json:item><name> </name></json:item></author><host><volume>353</volume><pages><last>2042</last><first>2041</first></pages><author></author><title>Lancet</title></host><title>Clozapine in drug‐induced psychosis in Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item><json:item><name> </name></json:item></author><host><volume>340</volume><pages><last>763</last><first>757</first></pages><author></author><title>N Engl J Med</title></host><title>Low‐dose clozapine for the treatment of drug‐induced psychosis in Parkinson's disease</title></json:item><json:item><author><json:item><name>CG Goetz</name></json:item><json:item><name>LM Blasucci</name></json:item><json:item><name>S Leurgans</name></json:item><json:item><name>EJ Pappert</name></json:item></author><host><volume>55</volume><pages><last>794</last><first>789</first></pages><author></author><title>Neurology</title></host><title>Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>53</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>13</total><last>S15</last><first>S3</first></pages><issn><json:string>0364-5134</json:string></issn><issue>S3</issue><subject><json:item><value>Research Articles</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1002/ana.10513</json:string></doi><id>8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</id><score>0.26613188</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Limitations of current Parkinson's disease therapy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><p>Copyright © 2003 Wiley‐Liss, Inc.</p></availability><date>2003</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Limitations of current Parkinson's disease therapy</title><author xml:id="author-1"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><affiliation>INSERM U455, Toulouse, University Hospital France</affiliation><affiliation>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Pierre</forename><surname>Payoux</surname></persName><roleName type="degree">MD</roleName><affiliation>INSERM U455, Toulouse, University Hospital France</affiliation><affiliation>Department of Nuclear Medicine, Toulouse, University Hospital France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Fabienne</forename><surname>Ory</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Joaquim J.</forename><surname>Ferreira</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><affiliation>Department of Neurology, Lisbon, Portugal</affiliation></author><author xml:id="author-5"><persName><forename type="first">Christine</forename><surname>Brefel‐Courbon</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><affiliation>INSERM U455, Toulouse, University Hospital France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Jean‐Louis</forename><surname>Montastruc</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003"></date><biblScope unit="volume">53</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">3</biblScope><biblScope unit="page" from="S3">S3</biblScope><biblScope unit="page" to="S15">S15</biblScope></imprint></monogr><idno type="istex">8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno><idno type="DOI">10.1002/ana.10513</idno><idno type="ArticleID">ANA10513</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2003</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Articles</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="45"><doi origin="wiley" registered="yes">10.1002/ana.v53:3+</doi><titleGroup><title type="supplementTitle">Neurogeneration and Prospects for Neuroprotection and Rescue in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="53">53</numbering><numbering type="journalIssue">S3</numbering><numbering type="supplement" number="3">3</numbering></numberingGroup><coverDate startDate="2003">2003</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="2" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.10513</doi><idGroup><id type="unit" value="ANA10513"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Research Articles</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2003 Wiley‐Liss, Inc.</copyright><eventGroup><event type="firstOnline" date="2003-03-24"></event><event type="publishedOnlineFinalForm" date="2003-03-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.1 mode:FullText source:FullText result:FullText" date="2010-02-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">S3</numbering><numbering type="pageLast">S15</numbering></numberingGroup><correspondenceTo>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA10513.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="101"></count><count type="wordTotal" number="10448"></count></countGroup><titleGroup><title type="main" xml:lang="en">Limitations of current Parkinson's disease therapy</title><title type="short" xml:lang="en">Limitations of PD Therapy</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>rascol@cict.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>Pierre</givenNames><familyName>Payoux</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Fabienne</givenNames><familyName>Ory</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af4"><personName><givenNames>Joaquim J.</givenNames><familyName>Ferreira</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Christine</givenNames><familyName>Brefel‐Courbon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jean‐Louis</givenNames><familyName>Montastruc</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U455, Toulouse, University Hospital France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Department of Nuclear Medicine, Toulouse, University Hospital France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="PT" type="organization"><unparsedAffiliation>Department of Neurology, Lisbon, Portugal</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Limitations of current Parkinson's disease therapy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Limitations of PD Therapy</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Limitations of current Parkinson's disease therapy</title></titleInfo><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><affiliation>INSERM U455, Toulouse, University Hospital France</affiliation><affiliation>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Payoux</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM U455, Toulouse, University Hospital France</affiliation><affiliation>Department of Nuclear Medicine, Toulouse, University Hospital France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabienne</namePart><namePart type="family">Ory</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joaquim J.</namePart><namePart type="family">Ferreira</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><affiliation>Department of Neurology, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brefel‐Courbon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><affiliation>INSERM U455, Toulouse, University Hospital France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Louis</namePart><namePart type="family">Montastruc</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2003</dateIssued><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">101</extent><extent unit="words">10448</extent></physicalDescription><abstract lang="en">Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Research Articles</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><detail type="issue"><caption>no.</caption><number>S3</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>3</number></detail><extent unit="pages"><start>S3</start><end>S15</end><total>13</total></extent></part></relatedItem><identifier type="istex">8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</identifier><identifier type="DOI">10.1002/ana.10513</identifier><identifier type="ArticleID">ANA10513</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2003 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001074 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001074 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E
|texte= Limitations of current Parkinson's disease therapy
}}
| This area was generated with Dilib version V0.6.29. |  |